BLAVIAL
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
HUMIRA (adalimumab) by AbbVie is tnf-alpha and blocks its interaction with the p55 and p75 cell surface tnf receptors. Approved for rheumatoid arthritis, crohn's disease, ulcerative colitis and 6 more indications. First approved in 2002.
HUMIRA (adalimumab) is a fully human monoclonal antibody that inhibits tumor necrosis factor (TNF-alpha), a key inflammatory cytokine. Approved in 2002, it treats 15 distinct indications spanning rheumatologic, dermatologic, gastroenterologic, and rare genetic diseases including rheumatoid arthritis, psoriasis, Crohn's disease, and multiple mucopolysaccharidoses. As a TNF inhibitor administered via subcutaneous injection, HUMIRA represents the foundational biologic therapy class for immune-mediated inflammatory diseases and remains a cornerstone treatment despite newer mechanism competitors.
$0.3BPart D
Mechanism of Action
TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in…
Indications (9)
Worked on HUMIRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.